Will Orlady represents biopharmaceutical, medical device, and technology companies in high-stakes intellectual property litigation.
Will draws on experience at every stage of litigation to advance or defend his client’s intellectual property claims. His practice covers disputes involving patent infringement, trade secret misappropriation, and intellectual property licensing and ownership (including related arbitration). Will has successfully represented both plaintiffs and defendants in disputes involving:
Small molecule drugs
Antibodies
Vaccines
Antibody-drug conjugates (ADCs)
Medical devices and other technologies
He regularly leads teams in litigation matters in district courts nationwide, the International Trade Commission (ITC), and in arbitration. Having been a central team member at eight trials, Will’s practice routinely involves complex, multijurisdictional disputes with global implications for his clients.
Will’s dedicated and team-driven approach stems from his time as a Division I swimmer. Will has deep experience spanning all phases of litigation, including pre-suit diligence, fact and expert discovery, claim construction, dispositive motions, and post-trial briefing, as well as preparing for, defending, and taking important fact and expert depositions.
In addition to his intellectual property practice, Will dedicates his time to pro bono matters and is a member of the PTAB Bar Association.
Experience
Will’s experience includes representing:
Sarepta in litigation involving novel treatments for Duchenne muscular dystrophy, resulting in a complete jury trial win
AbbVie in:
BPCIA litigation involving Humira®
District court litigation and in arbitration related to AbbVie innovative hepatitis C virus treatments Mavyret®, Viekira Pak®, and Technivie®
Intellia Therapeutics in litigation relating to CRISPR/Cas9 gene editing technology
Regeneron in patent litigation involving its groundbreaking antibody treatment for COVID-19 (REGENCOV®)
Merck Sharp & Dohme in a trade secret litigation relating to polysaccharide-protein conjugate vaccine formulations
A global pharmaceutical company in a competitor patent litigation involving multiple sclerosis drug products
A global pharmaceutical company in a confidential arbitration and license dispute relating to ADC technology
Philip Morris & Altria in a multi-jurisdictional dispute on innovative “heat-not-burn” and e-vapor technologies
Jaguar Land Rover in multi-forum patent litigation involving vehicle control technology
A multinational software company in a case that Latham took over following summary judgment and stipulation of direct infringement only four months before jury trial; obtained jury verdict of no induced infringement and judgment of zero damage
Qualifications
Bar Qualification
California
District of Columbia
Education
JD, University of Minnesota Law School, 2016 magna cum laude
BA in Neuroscience, University of Southern California, 2012
BA in Psychology, University of Southern California, 2012
A Latham team led by Mike Morin and David Frazier won the “Litigators of the Week” competition, alongside co-counsel at Finnegan, for their outstanding defense against a US$290 million patent infringement claim and securing a US$116 million award on behalf of Sarepta Therapeutics, in a one-week timed trial in Delaware.
In this edition, we explore developments in AI and digital health, cross-border licensing challenges, the pharmaceutical patent cliff, and other key areas.
Latham secured a US$115 million verdict for Sarepta Therapeutics and the University of Western Australia in a patent infringement claim against Nippon Shinyaku.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.